AIM ImmunoTech Inc. (AMEX:AIM) demonstrates remarkable capital efficiency with a Return on Invested Capital (ROIC) of 443.97%, significantly surpassing its peers in the biotechnology sector.The company's ROIC far exceeds its Weighted Average Cost of Capital (WACC), with a ratio of 76.10, indicating efficient use of capital to generate profits.In contrast, peers like Aytu BioPharma, Inc. (AYTU), iBio, Inc. (IBIO), and others show negative ROIC to WACC ratios, highlighting inefficiencies in capital utilizatio ...

Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s diseaseAlzheimer’s disease development program with positive data in successful Phase 1 and Phase 2a clinical trialsClear regulatory pathway following positive Type B meeting with U.S. FDAFDA has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease MIAMI, Sept. 22, 2025 (GLOBE NEWSWIRE) ...

BREAKING: Futures Fall With Market At Highs; Tesla Climbs After two high-profile failures, Pfizer (PFE) is clawing deeper into the obesity space with the $4.9 billion acquisition of Metsera (MTSR). Metsera, a small clinical-stage biotech company, is working on multiple approaches to weight loss. It has a potential weekly and monthly GLP-1-targeting drug — similar to Novo Nordisk's Wegovy — and a drug dosed monthly that mimics amylin. Amylin plays a role in regulating blood sugar levels, appetite and gastric ...

公司背景 - 内容由经验丰富的新闻记者团队独立制作 团队拥有数十年宝贵专业知识和经验[2][4] - 新闻团队覆盖全球主要金融和投资中心 在伦敦、纽约、多伦多、温哥华、悉尼和珀斯设有办事处和演播室[2] - 专家团队专注于中小型市值市场 同时为投资者提供蓝筹股、大宗商品和更广泛投资领域的最新信息[3] 内容覆盖范围 - 提供快速、可获取、信息丰富且可操作的商业和金融新闻内容 面向全球投资受众[2] - 市场报道范围包括但不限于生物技术和制药、采矿和自然资源、电池金属、石油和天然气、加密货币以及新兴数字和电动汽车技术[3] - 内容类型能够激发和吸引活跃的私人投资者[3] 技术应用 - 采用自动化和软件工具 包括生成式人工智能技术来辅助和增强工作流程[4][5] - 所有发布内容均经过人工编辑和创作 符合内容生产和搜索引擎优化的最佳实践标准[5] - 公司始终秉持前瞻性视角并积极采用新技术[4]

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a clinical stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, today announced that the first patient has been dosed in a Phase 2 clinical trial of SRSD107, a next-generation, long-acting Factor XI (FXI ...

UNIONDALE, NY, Sept. 22, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, announced that the Company entered into an agreement relating to potential advisory services. Management continues to evaluate a range of options for potential allocation of balance sheet resources, including the possibility of investing in digital assets. “Following our stockholders’ approval of all proxy items at the Septembe ...

MELBOURNE, Australia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Starpharma (ASX: SPL, US OTC: SPHRY), an innovative Australian biotechnology company, today announced the signing of a collaboration and license agreement with Genentech, a member of the Roche Group, to develop potential cancer therapies that leverage Starpharma’s proprietary DEP® drug delivery technology. Starpharma will receive an upfront payment of USD $5.5 million (~AUD $8.3 million), and is eligible for development, commercial, and net sales mile ...

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.â,,¢ ("MindWalk,†"we† or "us† ) (Nasdaq: HYFT), a Bio-Native AI company, today announced "Company,†a major advancement of its AI-designed GLP-1 therapeutics program. New insights from the Company's LensAlâ, g platform reveal a previously unrecognized connection between GLP-1 biology and a second, non- overlapping pathway central to healthy aging and systemic resilience. The findings support a first-in-class dual- pathway regimen in whi ...

WAYNE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the appointment of Kevin R. Lind to its Board of Directors. Mr. Lind brings more than 20 years of leadership in capital markets, strategy, business development and company building, including most recently guiding Longboard Pharmaceuticals to a multi-billion-dollar exit. “ ...